mTOR and cancer: insights into a complex relationship
DM Sabatini - Nature Reviews Cancer, 2006 - nature.com
Abstract mTOR (mammalian target of rapamycin) has come a long way since its humble
beginnings as a kinase of unknown function. As part of the mTORC1 and mTORC2 …
beginnings as a kinase of unknown function. As part of the mTORC1 and mTORC2 …
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully, H You, AJ Levine, TW Mak - Nature Reviews Cancer, 2006 - nature.com
The tumour-suppressor phosphatase with tensin homology (PTEN) is the most important
negative regulator of the cell-survival signalling pathway initiated by phosphatidylinositol 3 …
negative regulator of the cell-survival signalling pathway initiated by phosphatidylinositol 3 …
Current development of mTOR inhibitors as anticancer agents
S Faivre, G Kroemer, E Raymond - Nature reviews Drug discovery, 2006 - nature.com
Mammalian target of rapamycin (mTOR) is a kinase that functions as a master switch
between catabolic and anabolic metabolism and as such is a target for the design of …
between catabolic and anabolic metabolism and as such is a target for the design of …
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas, C Tran, IK Mellinghoff, DS Welsbie… - Nature medicine, 2006 - nature.com
Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic
activity in cancer trials, leading to confusion about the appropriate clinical setting for their …
activity in cancer trials, leading to confusion about the appropriate clinical setting for their …
mTOR and cancer therapy
JB Easton, PJ Houghton - Oncogene, 2006 - nature.com
Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the
targets of the mTOR kinase, are overexpressed or mutated in cancer. Rapamycin, the …
targets of the mTOR kinase, are overexpressed or mutated in cancer. Rapamycin, the …
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, H Hirte… - British journal of …, 2006 - nature.com
Standard cytotoxic treatments for neuroendocrine tumours have been associated with
limited activity and remarkable toxicity. A phase II study was designed to evaluate the …
limited activity and remarkable toxicity. A phase II study was designed to evaluate the …
Targeted therapy for metastatic renal cell carcinoma
RJ Motzer, RM Bukowski - Journal of clinical oncology, 2006 - ascopubs.org
The discovery of a relationship for the VHL tumor suppressor gene, hypoxia inducible factor-
1 alpha, and vascular endothelial growth factor in the growth of clear-cell renal cell …
1 alpha, and vascular endothelial growth factor in the growth of clear-cell renal cell …
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
KWL Yee, Z Zeng, M Konopleva, S Verstovsek… - Clinical Cancer …, 2006 - AACR
Abstract Purpose: Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits
the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth …
the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth …
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
E Buck, A Eyzaguirre, E Brown, F Petti… - Molecular cancer …, 2006 - AACR
The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers. One
important signaling pathway regulated by EGFR is the phosphatidylinositol 3′-kinase …
important signaling pathway regulated by EGFR is the phosphatidylinositol 3′-kinase …
Therapeutic targets: MTOR and related pathways
JE Dancey - Cancer biology & therapy, 2006 - Taylor & Francis
The mammalian target of rapamycin (mTOR), a protein kinase of the phosphatidylinositol 3-
kinase (PI3K)/Akt signaling pathway, has a central role in controlling malignant cellular …
kinase (PI3K)/Akt signaling pathway, has a central role in controlling malignant cellular …